35 results on '"Lutz, Catrin"'
Search Results
2. Mechanisms that clear mutations drive field cancerization in mammary tissue
3. Rat Models of Hormone Receptor-Positive Breast Cancer
4. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
5. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
6. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
7. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
8. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
9. Abstract PR10: Mammary epithelial architecture modulates field cancerization
10. Abstract A062: Somatic engineering of rat models to recapitulate human breast cancer evolution and heterogeneity
11. Mechanisms that clear mutations drive field cancerization in mammary tissue
12. Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
13. The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
14. In situ CRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer
15. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
16. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
17. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
18. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
19. Abstract 3488: Truncated FGFR2 - a clinically actionable oncogene in multiple cancers
20. Abstract PR006: A living biobank of patient-derived ductal carcinoma in situ (DCIS) Mouse-INtraDuctal (MIND) xenografts identifies multiple risk factors of invasive progression
21. Abstract IA012: Mammary epithelial architecture modulates field cancerization
22. Abstract PR003: Pioneering genetic rat models of Ductal Carcinoma in situ (DCIS)
23. Publisher Correction:Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)
24. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
25. Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
26. MYC promotes immune-suppression in TNBC via inhibition of IFN signaling
27. Abstract B37: Understanding DCIS initiation and progression using PDX and genetically engineered mouse and rat models
28. Truncated FGFR2is a clinically actionable oncogene in multiple cancers
29. In situCRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer
30. Abstract 5115: Establishing tumoroid and mouse models for functional validation of progression markers in DCIS
31. Abstract A01: Somatic engineering of the mammary gland for the development of novel mouse models of triple-negative breast cancer
32. The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review
33. Publisher Correction: Truncated FGFR2is a clinically actionable oncogene in multiple cancers
34. The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
35. The complex landscape of luminal breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.